{
  "id": "fda_guidance_chunk_0631",
  "title": "Introduction - Part 631",
  "text": "electronic copy of the guidance or send a fax request to 240-276-3151 to receive a hard copy. Please use the document number (Office GGP Rep will insert DOC number in parentheses) to identify the guidance you are requesting. Additional copies of this guidance document are also available from the Center for Biologics Evaluation and Research (CBER), Office of Communication, Outreach and Development (HFM-40), 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448, or by calling 1-800-835-4709 or 301-827-1800, or email ocod@fda.hhs.gov, or from the Internet at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm Contains Nonbinding Recommendations Table of Contents 1. Introduction............................................................................................................................................4 2. Foreword................................................................................................................................................4 2.1 What is Bayesian statistics?..................................................................................................................5 2.2 Why use Bayesian statistics for medical devices?................................................................................5 2.3 Why are Bayesian methods more commonly used now?.....................................................................6 2.4 When should FDA participate in the planning of a Bayesian trial?......................................................6 2.5 The Bayesian approach is not a substitute for sound science...............................................................6 2.6 What are potential benefits of using Bayesian methods?.....................................................................7 2.7 What are potential challenges using the Bayesian approach?...............................................................8 2.8 What software programs are available that can perform Bayesian analyses?.....................................10 2.9 What resources are available to learn more about Bayesian statistics?..............................................11 3. Bayesian Statistics................................................................................................................................11 3.1 Outcomes and Parameters..................................................................................................................12 3.3 What is a prior distribution?...............................................................................................................13 3.4 What is the likelihood of the observed data?......................................................................................15 3.5 What is the posterior distribution?......................................................................................................15 3.6 What is a predictive distribution?.......................................................................................................16 3.7 What is exchangeability?....................................................................................................................17 3.8 What is the Likelihood Principle?......................................................................................................19 4. Planning a Bayesian Clinical Trial.......................................................................................................19 4.1 Bayesian trials start with a sound clinical trial design........................................................................19 4.2 Selecting the relevant endpoints.........................................................................................................20 4.3 Collecting other important information: covariates............................................................................21 4.4 Choosing a comparison: controls........................................................................................................21 4.5 Initial information about the endpoints: prior distributions................................................................22 4.6 Borrowing strength from other studies: hierarchical models..............................................................25 4.7 Determining the sample size...............................................................................................................27 4.8 Assessing the operating characteristics of a Bayesian design.............................................................28 5. Analyzing a Bayesian Clinical Trial.........................................................................................................32 5.1 Summaries of the posterior distribution.............................................................................................32 5.2 Hypothesis testing..............................................................................................................................32 5.3 Interval estimation..............................................................................................................................32 5.4 Predictive probabilities.......................................................................................................................33 5.5 Interim analyses..................................................................................................................................34 5.6 Model Checking.................................................................................................................................35 5.7 Sensitivity Analysis............................................................................................................................36 5.8 Decision analysis................................................................................................................................36 6. Post-Market Surveillance.....................................................................................................................37 7. Technical Details..................................................................................................................................38 7.1 Suggested Information to Include in Your Protocol...........................................................................38 7.2 Simulations to Obtain Operating Characteristics................................................................................40 7.3 Model Selection..................................................................................................................................42 7.4 Checking Exchangeability using the Posterior Predictive Distribution..............................................43 7.5 Calculations........................................................................................................................................44 8. References............................................................................................................................................46 Guidance for Industry and FDA Staff Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials This guidance represents the Food and Drug Administration's (FDA's) current thinking",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 846720,
  "end_pos": 848256,
  "tokens": 512,
  "tags": [
    "design",
    "statistical",
    "regulatory",
    "clinical_trial",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.726Z"
}